GQ 1010
Alternative Names: BHV-1510; GQ-1010; PBI-410Latest Information Update: 21 Aug 2024
At a glance
- Originator Suzhou GeneQuantum Healthcare
- Developer Biohaven Pharmaceuticals; Suzhou GeneQuantum Healthcare
- Class Antibodies; Antineoplastics; Drug conjugates
- Mechanism of Action TROP2 antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase I/II Solid tumours
- Preclinical Colorectal cancer; Non-small cell lung cancer; Triple negative breast cancer
Most Recent Events
- 29 May 2024 Biohaven Pharmaceuticals plans a clinical trial for Carcinoma (Combination-therapy)
- 23 May 2024 Phase-I/II clinical trials in Solid tumours (Late-stage disease, Metastatic disease, Second-line therapy or greater, Inoperable/Unresectable) in China (Parenteral) (NCT06464055)
- 30 Apr 2024 Pyramid Biosciences plans a phase I/II trial for Solid tumours (Late-stage disease, Inoperable/Unresectable, Metastatic disease, Second-line therapy or greater) (IV, Infusion), in April 2024 (NCT06384807)